Targin® for Chronic Pain Management in Patients With Spinal Cord Injury

PHASE4CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

November 29, 2021

Study Completion Date

November 29, 2021

Conditions
Chronic Pain
Interventions
DRUG

Oxycodone Naloxone Combination

"A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator.~Oxycodone-Naloxone is available in the following oral dosages:~1. 5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride~2. 10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride~3. 20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride~4. 40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride"

Trial Locations (1)

V5Z 1M9

University of British Columbia, Vancouver

All Listed Sponsors
collaborator

Purdue Pharma, Canada

INDUSTRY

collaborator

International Collaboration on Repair Discoveries

OTHER

collaborator

Vancouver Coastal Health

OTHER_GOV

lead

University of British Columbia

OTHER

NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury | Biotech Hunter | Biotech Hunter